Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid vs pamidronate in children with severe osteogenesis imperfecta
2015-003539-37Phase 2
- Sponsor
- Novartis
- Start
- Mar 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in osteogenesis imperfecta (OI) comparing Zoledronic acid arm with Pamidronate arm (2 arms). Primary endpoint: Change in lumbar spine bone mineral density.
02
Drugs
zoledronic acidpamidronate
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on 2015-003539-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003539-37.